Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $10.14

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been given a consensus rating of “Hold” by the nine analysts that are presently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $10.14.

A number of equities research analysts recently issued reports on the stock. Needham & Company LLC restated a “buy” rating and issued a $5.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. Royal Bank of Canada restated a “sector perform” rating and issued a $4.00 target price on shares of Neumora Therapeutics in a report on Tuesday, March 4th. William Blair downgraded shares of Neumora Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, March 10th. HC Wainwright lowered their target price on shares of Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Finally, Bank of America lowered their target price on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a report on Monday, January 6th.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Neumora Therapeutics during the fourth quarter worth approximately $61,000. PNC Financial Services Group Inc. acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth $64,000. Quantbot Technologies LP acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth $92,000. PEAK6 LLC acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth $117,000. Finally, EntryPoint Capital LLC acquired a new position in shares of Neumora Therapeutics during the fourth quarter worth $135,000. 47.65% of the stock is currently owned by hedge funds and other institutional investors.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $1.13 on Tuesday. The firm has a 50 day simple moving average of $1.72 and a 200-day simple moving average of $7.90. The firm has a market cap of $183.04 million, a PE ratio of -0.60 and a beta of 2.59. Neumora Therapeutics has a 1-year low of $1.12 and a 1-year high of $17.19.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings data on Thursday, March 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. As a group, sell-side analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.